OVULATION INDUCTION (Female Models) Assisted Reproductive Technologies Ovulatory Trigger Timing: Administration when dominant follicle 18-20mm Dosage: 5,000-10,000 IU single dose Ovulation: 34-36 hours post-administration Mechanism: mimics natural LH surge Luteal Phase Support Dosage: 1500-2500 IU every 3-4 days Duration: 2 weeks post-ovulation Maintenance: corpus luteum progesterone production Alternative: exogenous progesterone (most common clinically) Controlled Superovulation Combination: FSH + hCG final maturation Models: IVF, assisted reproduction research Multiple follicles: synchronized development Precise timing: oocyte retrieval 34-36h post-hCG ADVANCED RESEARCH PROTOCOLS Dosage Male Models Rodents (Rats/Mice): Non-Human Primates Female Model Dosages Rodents: Rabbits/Primates: In Vitro Studies Primary Leydig Cells Concentration: 0.1-10 IU/mL (typically 1 IU/mL) Steroidogenesis: testosterone measurement ELISA 24-48h Gene expression: StAR, CYP11A1, 3-HSD (RT-qPCR) Viability: MTT, apoptosis (Annexin V) Signaling: Intracellular cAMP (ELISA/Radioimmunoassay) Granulosa cells Concentration: 1-10 IU/mL Luteinization: progesterone production Receptor expression: LHCGR, FSHR Proliferation: BrdU incorporation Testicular Explants: Organotypic culture: immature testicular tissue hCG: 0.5-5 IU/mL medium culture Maturation: seminiferous tubule development Spermatogenesis: Histological Analysis Reconstitution and Administration Methods hCG Preparation (Typically Lyophilized): Sales Presentation Lyophilized vial + diluent (bacteriostatic water or saline) Common concentrations: 5,000 IU, 10,000 IU per vial Reconstitution Protocol: Clean the stoppers on both vials with 70% alcohol Add diluent to the lyophilized hCG vial: 5,000 units 5mL 1,000 IU/mL 10,000 IU 10mL 1,000 IU/mL Slowly inject through the vial wall Gently swirl (DO NOT shake vigorously) Dissolving: 1-2 minutes, clear solution Verification: Clear, colorless solution Without particles or precipitate Discard if cloudy Storage: Administration Routes Intramuscular (IM) First choice, optimal bioavailability Subcutaneous (SC) Acceptable, bioavailability ~4050% IM Intraperitoneal (IP): Small rodents, preclinical research RESEARCH FAQ hCG vs
Chronic sciatica often indicates you need more than time and basic home remedies to achieve lasting relief
Symptoms of MTHFR mutations can vary but often include issues related to folate deficiency, such as fatigue, mood disturbances, and complications during pregnancy
The Lancet, 336(8712), 392-395
Target Dose (Monotherapy/Combination): The common target dose used in major clinical trials is 2.4 mg per week
Handle using proper laboratory precautions, including gloves and aseptic techniques, to prevent contamination
